Table 2.
fMRI activations as found for the contrast modelling reward salience.
| L/R/M | Z | NV | Max. x/y/z | Z | NV | Max. x/y/z | Z | NV | Max. x/y/z | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| STUDY 1 (INDEX STUDY) | HC (n = 16) | SX (n = 16) | HC > SX | ||||||||
| VLPFC/Ant. Ins., BA 47 | R | 5.19* | 119 | 42/24/−15 | 3.67 | 15 | 39/21/−15 | ||||
| Ant. Cingulate, BA 9/32 | 4.43 | 107 | 9/39/21 | ||||||||
| DLPFC, BA 9/46 | R | 4.26 | 24 | 42/36/21 | |||||||
| STUDY 2 (REPLICATION STUDY) | HC (N = 12) | SX (n = 12) | HC >SX | ||||||||
| VLPFC/Ant. Ins., BA 47 | R | 4.68* | 86 | 36/33/−15 | 3.26* | 57 | 33/30/−9 | ||||
| 4.19* | 48 | 45/18/−18 | |||||||||
| L | 3.45* | 35 | −48/21/−6 | ||||||||
| Ant. Cingulate, BA 24/32 | M | 3.78* | 263 | −3/36/15 | 3.70* | 137 | 0/27/27 | ||||
| Med. frontal gyrus, BA 8/9 | L | 3.91* | 112 | −15/42/30 | |||||||
| Ventral Striatum | R | 4.19* | 77 | 9/15/0 | 3.23 | 17 | 12/12/−6 | ||||
| L | 3.74* | 20 | −9/9/−3 | ||||||||
| Med. Frontal gyrus, BA 10 | R | 4.10 | 34 | 30/51/6 | |||||||
| Post. Cingulate, BA 23/31 | 3.97* | 52 | 0/−9/27 | 3.80 | 51 | −3/−21/30 | |||||
| Thalamus | 3.49* | 25 | −3/−9/9 | ||||||||
| Hippocampal area | L | 3.45* | 29 | −21/−33/−6 | |||||||
| R | 3.35* | 22 | 18/−36/−6 | ||||||||
| Occipital cortex BA18 | L | 3.97* | 108 | −18/102/−3 | 4.01 | 22 | −18/−99/−6 | ||||
| R | 4.27* | 70 | 21/−99/0 | 3.61 | 41 | 12/−93−/−3 | |||||
| Cerebellum | R | 3.51* | 25 | 27/−54/−27 | |||||||
| STUDY 3 (CONTROLS FOR STUDY 4) | HC (n = 11) | ||||||||||
| VLPFC/Ant. Ins., BA 47 | R | 5.97∼ | 13 | 30/21/−9 | |||||||
| STUDY 4 (RLS-STUDY) | RLS OFF MEDS (n = 12) | RLS ON MEDS (n = 12) | OFF > ON MEDS | ||||||||
| VLPFC/Ant. Insula, BA 47 | R | 3.65 | 31 | 38/28/−18 | |||||||
| L | 3.57 | 31 | −36/20/−14 | ||||||||
| DLPFC, BA 9/46 | R | 4.18 | 47 | 52/26/34 | |||||||
| DLPFC, BA 9/44 | 3.39 | 22 | 50/18/24 | ||||||||
| Precentral gyrus, BA 6 | L | 4.15 | 74 | −42/4/28 | 4.56* | 49 | −44/4/24 | ||||
| Precentral gyrus, BA 4 | R | 4.03 | 20 | 44/−2/36 | |||||||
| Inf. temporal gyrus, BA 37 | R | 3.88 | 35 | 64/−46/−8 | |||||||
| STUDY 5 (OLANZAPINE STUDY) | HC PLACEBO (n = 8) | HC OLANZAPIN (n = 8) | PLACEBO > OLANZAPINE | ||||||||
| No significant activation | |||||||||||
Brain activation related to the salience of outcome events (receipt of high > receipt of low > receipt of no < omission of low < omission of high reward. Contrast weights; 4 -1-6 -14). Significant activation clusters are listed separately for each group and for the between group comparisons. The activations reported in healthy subjects and patients were significant at p <0.001 uncorrected for multiple comparisons on the voxel-level or as indicated (∼p < 0.005 FWE corrected; *p < 0.05 FDR corrected 1), interactions in study 2 at p < 0.005 at the voxel-level. Coordinates are SPM/MNI.